ScottHuntingtonMDMPH, MSHP

PubMed

• Cost-effectiveness of Enasidenib versus conventional care for older patients withmutant refractory/relapsed AML.
  Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan
  Leukemia & Lymphoma. 2024-11-19
• Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.
  Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha
  Haematologica. 2024-11-14
• Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocyti...
  Scott F Huntington, Beenish S Manzoor, Dureshahwar Jawaid, Justin T Puckett, Nnadozie Emechebe
  Journal of Managed Care & Specialty Pharmacy. 2024-10-01

Abstracts/Posters

• Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neopl...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Populatio...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and ...
  Scott F. Huntington, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018